Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022). 05 March 2024 Company Announcement No. 06 Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) about the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Pharma Equity Group的子公司（Reponex Pharmaceuticals A/s）已收到欧洲专利局（EPO）关于决定授予其促进伤口愈合的药物组合物专利（RNX-022）的通知。2024年3月5日第06号公司公告Pharma Equity Group的子公司（Reponex Pharmaceuticals A/s）已收到欧洲专利局（EPO）关于授予其促进伤口愈合药物组合物专利（RNX-022）的通知。

Today's announcement signifies a significant milestone as the EPO has approved EP patent No. 3145533, encompassing Reponex' innovative treatment method. This method consists of topically applying a hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF), sucralfate, and hyaluronan to accelerate wound healing.

今天的公告标志着一个重要的里程碑，因为EPO已经批准了EP专利号3145533，涵盖了Reponex的创新治疗方法。该方法包括局部应用含有粒细胞巨噬细胞集落刺激因子（GM-CSF），硫糖铝和透明质酸的水凝胶以加速伤口愈合。

The combination helps stimulating the proliferation of cells related to the healing process and tissue regeneration. 'We are very pleased that the EPO has now approved the patent application for our drug candidate RNX-022, allowing us to protect our product in such a crucial commercial domain,' says Thomas Kaas Selsø, CEO of Pharma Equity Group A/S.

这种组合有助于刺激与愈合过程和组织再生有关的细胞增殖。”Pharma Equity Group a/S首席执行官托马斯·卡斯·塞尔塞（Thomas Kaas Selsø）说：“我们很高兴EPO现在批准了我们候选药物RNX-022的专利申请，使我们能够在如此关键的商业领域保护我们的产品。”。

Wound healing represents a significant challenge for many individuals, necessitating the development of enhanced treatment methodologies to address the complexities and improve patient outcomes effectively. According to Grand View Research, the global wound treatment market was valued at USD 21.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.15% from 2023 to 2030.

伤口愈合对许多人来说是一个重大挑战，因此需要开发增强的治疗方法来解决复杂性并有效改善患者预后。根据大视野研究（Grand View Research），2022年全球伤口治疗市场价值214亿美元，预计2023年至2030年将以4.15%的复合年增长率（CAGR）增长。

The patent is valid until 2035. With the attainment of full Supplementary Protection Certificate (SPC) extension, the validity will extend until 2040. For further information, please contac.

该专利有效期至2035年。随着全面补充保护证书（SPC）延期，有效期将延长至2040年。欲了解更多信息，请联系。

Attachment

附件

2024 03 05 - Announcement no 06 - ENG

2024 03 05-第06号公告-工程